Barbara J. Gitlitz, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses results and key takeaways from The Genomics of Young Lung Cancer Study.

This study showed that it is feasible to think outside the box when considering patient recruitment. In this study, researchers used social media and the Internet to recruit patients. In total, Gitlitz says, 44% of patients came through these means.

Researchers greatly exceeded their statistical expectations, Gitlitz says. For patients with lung adenocarcinoma, researchers set a bar close to the Lung Cancer Mutation Consortium and wanted to demonstrate an increase in actionable mutations from 35% to 50%. In actuality, they found actionable mutations in 76% of patients.

View more from the 2015 World Conference on Lung Cancer

Videos

Barbara J. Gitlitz, MD, from the University of Southern California, discusses results and key takeaways from The Genomics of Young Lung Cancer Study.

Dr. Gitlitz Discusses the Genomics of Young Lung Cancer Study

rofessor of Clinical Medicine, Keck Hospital of USC Norris Comprehensive Cancer Center, discusses treating patients with 

 exon 20 insertion mutations in lung cancer.

Exon 20 insertion mutations are the third most common type of 

 lung cancer present with, says Gitlitz. While this mutation will show up in a report as an 

 mutation, it does not respond to any currently available EGFR inhibitors. It is important to be aware that a patient with an 

Exon 20 insertion mutations are currently a target without a treatment, says Gitlitz. More clinical trials are needed.

Barbara J. Gitlitz, MD, associate professor of Clinical Medicine, Keck Hospital of USC Norris Comprehensive Cancer Center, discusses treating patients with EGFR exon 20 insertion mutations in lung cancer.

Barbara J. Gitlitz, MD

Articles

Dr. Gitlitz Discusses the Genomics of Young Lung Cancer Study

Dr. Gitlitz on EGFR Exon 20 Insertion Mutations in Lung Cancer